Major Publications in the Critical Care Pharmacotherapy Literature: 2023

• Published in: Critical care explorations 2024-10, Vol.6 (10), p.e1162
• Main Authors: Murray, Brian, Athale, Janhavi, Balk, Robert A, Behal, Michael L, Brown, Judah E, Chanas, Tyler, Dumitru, Roxana, Gifford, Dalton C, Hohlfelder, Benjamin, Jones, Honey M, Makic, Mary Beth F, Rausen, Michelle S, Sacco, Alicia J, Sines, Benjamin J, Gurnani, Payal K
• Format: Article
• Language: English
• Subjects: Critical Care - methods; Critical Illness - therapy; Drug Therapy - methods; Humans
• ISSN: 2639-8028; 2639-8028
• DOI: 10.1097/CCE.0000000000001162

We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023. PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update. Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article. Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature. The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion. This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.